MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

Home・Aktien・Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals Inc

Geschlossen

BrancheGesundheitswesen

21.46 0.19

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

21.46

Max

21.46

Schlüsselkennzahlen
By Trading Economics
Einkommen	-1.6M -21M
Verkäufe	14M 54M
Gewinnspanne	-39.611
Angestellte	178
EBITDA	-3.8M -23M

Empfehlungen
By TipRanks
Empfehlungen	Neutral
12-Monats-Prognose	-2.61% downside

Dividenden
By Dow Jones
Nächstes Ergebnis	5. Mai 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	1B 2.2B
Vorheriger Eröffnungskurs	21.27
Vorheriger Schlusskurs	21.46

Nachrichtenstimmung

By Acuity

50%

154 / 349 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

6.26 / 7.47 Unterstützung & Widerstand

Day One Biopharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

3. Apr. 2026, 04:27 UTC

Wichtige Nachrichtenereignisse

Singapore PM Warns That Fallout From Mideast War Could Outlast Conflict

3. Apr. 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3. Apr. 2026, 18:30 UTC

Wichtige Nachrichtenereignisse

An F15-E Just Went Down in Iran. What to Know About the $30 Million Jet. -- Barrons.com

3. Apr. 2026, 18:14 UTC

Market Talk

Eli Lilly Seen as Possible GLP-1 Leader With New Pill Approval -- Market Talk

3. Apr. 2026, 17:50 UTC

Market Talk

Microsoft's AI Development Will Weigh on Near-Term Azure Growth -- Market Talk

3. Apr. 2026, 17:44 UTC

Akquisitionen, Fusionen, Übernahmen

SBA Stock Just Had a Big Day. Why It's Suddenly Hot. -- Barrons.com

3. Apr. 2026, 16:50 UTC

Wichtige Nachrichtenereignisse

An F15-E Just Went Down in Iran. What to Know About the $90 Million Jet. -- Barrons.com

3. Apr. 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3. Apr. 2026, 16:12 UTC

Ergebnisse

Oil Stocks Look Tapped Out. Why It's Time to Move Into Other Sectors. -- Barrons.com

3. Apr. 2026, 15:56 UTC

Market Talk

Wichtige Nachrichtenereignisse

Crypto Markets May Be Active Over Holiday Weekend -- Market Talk

3. Apr. 2026, 15:56 UTC

Market Talk

Wichtige Nachrichtenereignisse

Global Equities Roundup: Market Talk

3. Apr. 2026, 15:56 UTC

Market Talk

Wichtige Nachrichtenereignisse

Global Forex and Fixed Income Roundup: Market Talk

3. Apr. 2026, 15:20 UTC

Wichtige Nachrichtenereignisse

Berkshire, Travelers Join U.S. Plan to Insure Shippers in the Hormuz Strait -- Barrons.com

3. Apr. 2026, 15:08 UTC

Akquisitionen, Fusionen, Übernahmen

OpenAI Makes Surprise Media Acquisition Ahead of IPO. Why It Will Fail. -- Barrons.com

3. Apr. 2026, 14:11 UTC

Market Talk

Wichtige Nachrichtenereignisse

Oil Shock From War in Iran May Show Up In 2Q Job Growth Data -- Market Talk

3. Apr. 2026, 12:56 UTC

Market Talk

Treasury Yields, Dollar Higher Following Robust March Hiring -- Market Talk

3. Apr. 2026, 08:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3. Apr. 2026, 08:01 UTC

Market Talk

Global Equities Roundup: Market Talk

3. Apr. 2026, 08:01 UTC

Market Talk

Meituan's Profitability Likely to Improve This Year -- Market Talk

3. Apr. 2026, 07:45 UTC

Market Talk

LG Electronics Could Post Above-Consensus 1Q Earnings -- Market Talk

3. Apr. 2026, 06:17 UTC

Market Talk

Naver Likely to Post Below-Consensus 1Q Earnings -- Market Talk

3. Apr. 2026, 06:17 UTC

Market Talk

Global Equities Roundup: Market Talk

3. Apr. 2026, 04:33 UTC

Market Talk

China Merchants Port Earnings Likely to Recover This Year -- Market Talk

3. Apr. 2026, 04:33 UTC

Market Talk

Global Equities Roundup: Market Talk

3. Apr. 2026, 04:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

3. Apr. 2026, 04:01 UTC

Market Talk

Posco Holdings 1Q Earnings Could Fall Short of Expectations -- Market Talk

3. Apr. 2026, 02:01 UTC

Market Talk

India Consumer-Staple Companies Likely to Post Broadly Steady 4Q Results -- Market Talk

3. Apr. 2026, 01:59 UTC

Market Talk

Sea's Shopee E-Commerce Platform Likely in Reinvestment Phase -- Market Talk

3. Apr. 2026, 01:44 UTC

Market Talk

Samsung Likely to Report Record Quarterly Earnings in 2026 -- Market Talk

3. Apr. 2026, 01:22 UTC

Market Talk

Dollar Could Hit 160 Yen in Thin Holiday Trading -- Market Talk

Peer-Vergleich

Kursveränderung

Day One Biopharmaceuticals Inc Prognose

Kursziel

By TipRanks

-2.61% Nachteil

12-Monats-Prognose

Durchschnitt 20.86 USD -2.61%

Hoch 21.5 USD

Tief 17 USD

Basierend auf 9 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Day One Biopharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

9 ratings

Buy

Halten

Sell

Basierend auf 9 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Day One Biopharmaceuticals Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

6.26 / 7.47Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

All events are bullish.

All events are bearish.

Stimmung

By Acuity

154 / 349 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.